McKesson Corporation (MCK) displayed varied performance, with the stock underperforming against competitors on certain days, while seeing gains on others. The bio-tech company reported a 26% YTD gain, boosted by factors such as increased institutional ownership, which stands at
88%, and strong revenue growth. McKesson's fourth quarter results for fiscal 2024 demonstrated a positive turnaround, despite earlier reports of earnings missing estimates. The company hit its 52-week high multiple times. Notably, McKesson has introduced an FDA-approved prostate cancer drug, bolstering the company's portfolio and potential growth. Insider trading activities were recorded, with both the Director and the EVP & Chief HR Officer selling shares. Despite some negative reports, overall investor sentiment remains high, with many recommending the company as a
long-term buy and a
top momentum stock. McKesson's intrinsic value is considered significantly higher than its current share price, hinting at a potentially undervalued stock.
Mckesson Corporation MCK News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Sun, 23 Jun 2024 19:22:56 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor 1
